Cipla to acquire US-based InvaGen and Exelan for $550 mn

566 views Leave a comment

New Delhi: Drug vital Cipla has entered into agreements to acquire US-based InvaGen Pharmaceuticals and Exelan Pharmaceuticals, owned by one of a promoters of Hetero Group, in an all money transaction of $550 million (approx Rs 3,652 crore).

The company’s “UK arm Cipla EU has entered into decisive agreements to acquire dual US-based companies, InvaGen Pharmaceuticals Inc and Exelan Pharmaceuticals Inc.

Cipla logo. Image courtesy: logo. Image courtesy:

Cipla logo. Image courtesy:

“The transaction being theme to certain shutting conditions, is valued during $550 million and will be an all money transaction”, Cipla pronounced in a statement.

This merger will give Cipla scale in a US generics marketplace by a far-reaching trimming product portfolio in CNS, CVS, anti-infectives, diabetes as good as other value-added generics, it said.

Commenting on a acquisition, Cipla MD and Global CEO Subhanu Saxena said: “This investment is in line with Cipla’s plan to grow a share in a US curative market.”

The association sees InvaGen as a clever vital fit with a applicable opposite portfolio as good as a clever marketplace and patron presence, he said.

With a internal production trickery it can offer strengthen a participation and joining to offer patients in a country, he added.

InvaGen offers a vast ability production bottom in Hauppauge, NY and a learned US-based RD organization. The merger of InvaGen pharmaceuticals also provides Cipla with about 40 authorized ANDAs, 32 marketed products, and 30 tube products that are approaching to be authorized over a subsequent 4 years, Cipla said.

The merger of Exelan Pharmaceuticals provides Cipla entrance to supervision and institutional marketplace in a US, Cipla said.

“We are assured that a multiple of InvaGen and Cipla will significantly raise a product portfolio offering, including specialty products, to a US patients and will give InvaGen entrance to Cipla’s tellurian imagination and presence,” InvaGen Pharmaceuticals Inc boss and CEO
Sudhakar Vidiyala said.

  • ibibo picks minority interest in hotel resolution organisation Djubo

    ibibo picks minority interest in hotel resolution organisation Djubo

  • ITC denies receiving notice on additional lead in Yippee noodles

    ITC denies receiving notice on additional lead in Yippee noodles

  • India a really critical marketplace for us: IKEA

    India a really critical marketplace for us: IKEA

Commenting on a development, Hetero said: “Hetero would like to explain that a stream sale of Invagen pharmaceuticals is a sale of vital investment by a Hetero upholder organisation that has a opposite product portfolio than Hetero.

InvaGen Pharmaceuticals Inc, is not related directly to a flagship companies of a Hetero organisation i.e. Hetero Drugs Ltd or Hetero Labs Ltd.

Hetero has now 130 ANDAs filed in US. The association will continue to strengthen a participation in US marketplace by investing in US Generics and specialty products by a auxiliary organisation Camber Pharmaceuticals Inc in US.”

Shares of Cipla were currently trade during Rs 662.65 on a BSE, adult 1.13 percent from a prior close.